Abstract:The search for novel drug scaffolds that can improve effectiveness and safety through drug conjugates is a promising approach. Consequently, drug conjugates constitute a dynamic field of study and advancement within medicinal chemistry. This research demonstrates the conjugation of diclofenac and mefenamic acid with sulfa drugs and their screening for urease inhibition. These conjugates' structural confirmation was performed using elemental analysis and spectroscopic methods, including IR, 1H NMR, and 13C NMR. Diclofenac conjugated with sulfanilamide (4), sulfacetamide (10), and mefenamic acid conjugated with sulfanilamide (12), and sulfamethoxazole (17) was found potent and demonstrated urease inhibition competitively, with IC50 (μM) values 3.59 ± 0.07, 5.49 ± 0.34, 7.92 ± 0.27, and 8.35 ± 0.26, respectively. Diclofenac conjugated with sulfathiazole (6), sulfamerazine (8), and sulfaguanidine (11), while mefenamic acid conjugated with sulfisoxazole (13), sulfathiazole (14), and sulfadiazine (15) exhibited a mixed mode of urease inhibition. The IC50 (μM) values were 16.19 ± 0.21, 9.50 ± 0.28, 4.35 ± 0.23, 15.86 ± 0.25, 14.80 ± 0.27, and 7.92 ± 0.27, respectively. Furthermore, molecular docking studies were employed to predict the binding pose of competitive inhibitors at the urease active site. These conjugates generated stable complexes with the urease protein observed through molecular dynamics (MD) simulations, where no conformational changes occurred throughout the simulations. These results highlight the potential for approved therapeutic molecule conjugates to give rise to new categories of pharmacological agents for urease inhibition. The structural similarity of sulfonamides with urea allows them to compete with urea for binding to the active site of the urease enzyme. Sulfonamides and nonsteroidal anti-inflammatory drugs (NSAIDs) can interact hydrophobically with the active site of the urease enzyme, which may disturb its structure and catalytic activity. Therefore, these conjugates may be helpful in the development of novel pharmacological agents for the treatment of a variety of illnesses in which the urease enzyme is involved.

Synthesis, Evaluation and Mechanism Exploration of 2-(N-(3-nitrophenyl)-n-phenylsulfonyl)aminoacetohydroxamic Acids As Novel Urease Inhibitors.

Identification of (N-aryl-N-arylsulfonyl)aminoacetohydroxamic acids as novel urease inhibitors and the mechanism exploration

Synthesis and Biological Evaluation of Dithiobisacetamides as Novel Urease Inhibitors

Synthesis and Biological Evaluation of Triazolones/oxadiazolones As Novel Urease Inhibitors

Synthesis of novel 2-mercapto-1,3,4-oxadiazole derivatives as potent urease inhibitors: In vitro and in silico investigations

Synthesis and Structure-Activity Relationship Studies of N-monosubstituted Aroylthioureas As Urease Inhibitors.

The Synthesis and Evaluation of Phenoxyacylhydroxamic Acids As Potential Agents for Helicobacter Pylori Infections

Synthesis, Molecular Docking and Kinetic Properties of Β-Hydroxy-β-phenylpropionyl-hydroxamic Acids As Helicobacter Pylori Urease Inhibitors

Exploration of thiazine Schiff bases as promising urease inhibitors: Design, synthesis, enzyme inhibition, kinetic analysis, ADME/T evaluation, and molecular docking studies

New acetylphenol-based acyl thioureas broaden the scope of drug candidates for urease inhibition: synthesis, in vitro screening and in silico analysis

3-Arylpropionylhydroxamic Acid Derivatives As Helicobacter Pylori Urease Inhibitors: Synthesis, Molecular Docking and Biological Evaluation

Synthesis and Evaluation of Some Novel 1,3-Dimethylbarbituric Acid Derivatives as Potent Anti-Urease Agents: Comprehension through In Vitro, Molecular Docking, and DFT Investigations

Synthesis and Evaluation of N-analogs of 1,2-Diarylethane As Helicobacter Pylori Urease Inhibitors.

N-monosubstituted Thiosemicarbazide As Novel Ure Inhibitors: Synthesis, Biological Evaluation and Molecular Docking

Flavonoid analogues as urease inhibitors: Synthesis, biological evaluation, molecular docking studies and in-silico ADME evaluation

The Synthesis, Structure and Activity Evaluation of Pyrogallol and Catechol Derivatives As Helicobacter Pylori Urease Inhibitors

Synthesis and structure–activity relationship of thiobarbituric acid derivatives as potent inhibitors of urease

Molecular Docking and Molecular Dynamics Simulations of the Urease Inhibitory Activity of 2,3‐Dihydroxybenzohydrazide Derivatives

N -monoarylacetothioureas as potent urease inhibitors: synthesis, SAR, and biological evaluation.

Exploring the Potential of New Benzamide-Acetamide Pharmacophore Containing Sulfonamide as Urease Inhibitors: Structure-Activity Relationship, Kinetics Mechanism, and In Silico Studies

Arylamino Containing Hydroxamic Acids As Potent Urease Inhibitors for the Treatment of Helicobacter Pylori Infection.